Role of Flexibility in Protein-DNA-Drug Recognition: The Case of Asp677Gly-Val703Ile Topoisomerase Mutant Hypersensitive to Camptothecin by D'Annessa, Ilda et al.
Hindawi Publishing Corporation
Journal of Amino Acids
Volume 2012, Article ID 206083, 8 pages
doi:10.1155/2012/206083
Research Article
Role of Flexibility in Protein-DNA-Drug Recognition:
The Case of Asp677Gly-Val703Ile Topoisomerase Mutant
Hypersensitive to Camptothecin
Ilda D’Annessa,1 CinziaTesauro,1 Paola Fiorani,1 GiovanniChillemi,2 SilviaCastelli,1
Oscar Vassallo,1 GiovanniCapranico,3 and AlessandroDesideri1
1National Research Council (CNR) and Department of Biology, University of Rome Tor Vergata, Via Della Ricerca Scientiﬁca,
Rome 00133, Italy
2CASPUR, Via dei Tizii 6b, Rome 00185, Italy
3Department of Biochemistry “Giovanni Moruzzi,” University of Bologna, Via Irnerio 48, 40126 Bologna, Italy
Correspondence should be addressed to Alessandro Desideri, desideri@uniroma2.it
Received 11 May 2011; Accepted 7 October 2011
Academic Editor: Alice Vrielink
Copyright © 2012 Ilda D’Annessa et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Topoisomerases I are ubiquitous enzymes that control DNA topology within the cell. They are the unique target of the
antitumor drug camptothecin that selectively recognizes the DNA-topoisomerase covalent complex and reversibly stabilizes it.
The biochemical and structural-dynamical properties of the Asp677Gly-Val703Ile double mutant with enhanced CPT sensitivity
have been investigated. The mutant displays a lower religation rate of the DNA substrate when compared to the wild-type protein.
Analyses of the structural dynamical properties by molecular dynamics simulation show that the mutant has reduced ﬂexibility
and an active site partially destructured at the level of the Lys532 residue. These results demonstrate long-range communication
mechanism where reduction of the linker ﬂexibility alters the active site geometry with the consequent lowering of the religation
rate and increase in drug sensitivity.
1.Introduction
Human DNA topoisomerase I (hTop1) catalyzes the relax-
ation of supercoiled DNA through the transient cleavage of
one strand of a DNA duplex and is fundamental to processes
such as replication, recombination, and transcription [1–3].
The enzyme is composed of 765 amino acids, and the crystal
structure of the N-terminal truncated protein (topo70)
together with proteolytic experiments has shown that the
enzyme is composed of four diﬀerent domains: the NH2-
terminal domain (residues 1–214), the core domain (215–
635), the linker domain (636–712), and the COOH-terminal
domain (713–765) [4–6]. Changes in DNA topology are
achieved by introducing a transient break of the phospho-
diester bond of one strand in the duplex DNA. The phos-
phodiester bond energy is preserved during catalysisthrough
the formation of a transient covalent phosphotyrosine bond
between the catalytic Tyr723 and the 3 -end of the broken
DNA strand. After changing the linking number a second
nucleophilic attack, driven by the 5 -hydroxyl DNA end,
restores an intact double-stranded DNA, and the enzyme is
released [6].
Eukaryotic topoisomerase I is the target of the antitumor
drug camptothecin (CPT), which reversibly stabilizes the
cleavable intermediate complex formed in the catalytic
cycle of the enzyme, slowing the religation step of the
enzyme. The stalled topoisomerase I may then collide with
the progression of the replication fork producing lethal
double-strand DNA breaks and cell death [7]. An important
contribution toward the understanding of the interaction of
CPT with topoisomerase I and DNA was provided by the
crystal 3D structure of the ternary complex between topo70
covalently linked to DNA and the CPT derivative topotecan
(TPT) [8]. The structure shows that the drug intercalates
into the DNA duplex and moves the 5 -hydroxyl end of the
DNA away from the scissile phosphate. This misalignment
of the two ends likely slows down the religation step [8].
In addition to the eﬀects on the religation reaction, CPT2 Journal of Amino Acids
binding also reduces the linker domain mobility [9], as
recently conﬁrmed by molecular dynamics simulation of the
ternary hTop1-DNA-TPT complex [10]. The presence of the
drug aﬀects not only the mobility of the linker domain but
also the geometry of the active site, being the drug in direct
interaction with Lys532 for all the simulation time [10].
This long-range eﬀect results in linker domain showing a
deﬁned electron density in the structure of the topotecan-
DNA-topo70 ternary complex, but not in that of the DNA-
topo70 binary complex crystallized in the same conditions
[8].
In a previous report [11], the presence of two mutations
(Asp677Gly and Val703Ile) in the linker domain was shown
to confer increased CPT sensitivity to the hTop1 in yeast
cells. The presence of the linker domain has been shown
to be required for full inhibition of hTop1 by CPT [12].
In the case of the mutation Ala653Pro that confers a drug
resistance phenotype to Top1, a combined experimental
and simulative approach demonstrated that drug resistance
is associated with increased linker mobility, which aﬀects
the eﬃciency of the religation process [9]. A perturbed
linker dynamics coupled to a reduced religation rate has
beenalsoreportedfortheLys681Ala-linker-locatedmutation
[13] and a correlation between changes in linker ﬂexibility
and the enzyme speciﬁc activity has been proposed based
on the characterization of the Ala653Pro-Thr718Ala double
mutant [14]. Therefore, the current knowledge suggests that
mutations in the linker domain can aﬀect DNA binding and
CPT sensitivity of hTop1, although the exact mechanism
remains to be elucidated.
Inthepresentpaper,wehaveinvestigatedtheAsp677Gly-
Val703Ile double mutant to ﬁnd a molecular explanation for
its CPT hypersensitivity. Through a combined experimental
and molecular dynamics approach, we provide evidence
that the CPT-hypersensitive double mutant displays a lower
religation rate due to a displacement in the active site of
the Lys532 residue. Moreover, the mutant displays a lower
linker ﬂexibility conﬁrming the crucial role of this domain in
controlling the drug sensitivity of human Top1.
2.ExperimentalProcedures
2.1. Yeast Strain and Plasmids. Camptothecin was dissolved
in Me2SO to a ﬁnal concentration of 4mg/mL and stored
at 20◦C. Anti-FLAGM2 aﬃnity gel, FLAG peptide, and
M2 monoclonal antibody were purchased from Sigma.
Saccharomyces cerevisiae strain EKY3 (ura3–52, his3200,
leu21, trp163, top1::TRP1, MATα) was described previ-
ously [15, 16]. Plasmid YEpGAL1-wild-type in which the
human topoisomerase I is expressed under the galactose
inducible promoter in a multicopy plasmid was described
previously [17]. Asp677Gly-Val703Ile was generated by
oligonucleotide-directed mutagenesis of the YEpGAL1-wild-
type. The epitope-tagged construct YEpGAL1-e-wild-type
contains the N-terminal sequence FLAG: DYKDDDDY
(indicated with “e”), recognized by the M2 monoclonal
antibody. The epitope tag was subcloned into YEpGAL1-
Asp677Gly-Val703Ile to produce YEpGAL1-e-Asp677Gly-
Val703Ile.
2.2. Puriﬁcation of DNA Topoisomerase I. To purify the
topoisomeraseIepitope-taggedEKY3cellsweretransformed
with YEpGAL1-e-wild-type and YEpGAL1-e-Asp677Gly-
Val703Ile, grown on SC-uracil plus 2% dextrose and diluted
1:100 in SC-uracil plus 2% raﬃnose. At an optical density
A595 of 1.0, the cells were induced with 2% galactose for
6h. Cells were then harvested by centrifugation, washed
with cold water, and resuspended in 2mL buﬀer/g cells
using a buﬀer containing 50mM Tris, pH 7.4, 1mM EDTA,
1mM ethylene glycol-bis(2-aminoethylether)-N, N, N ,N  -
tetraacetic acid, 10% (v/v) glycerol completed with protease
inhibitors cocktail (Roche 1836153) and supplemented with
0.1mg/mL sodium bisulﬁte and 0.8mg/mL sodium ﬂuoride.
After addition of 0.5 volume of 425–600μm diameter
glass beads the cells were disrupted by vortexing for 30s
alternating with 30s on ice. The lysate was centrifuged and
KCl (ﬁnal concentration 0.15M) was added to the sample
prior to loading onto 2mL ANTI-FLAG M2 aﬃnity gel
column equilibrated as described in the technical bulletin
(Sigma). The column was washed with 20 column volumes
of TBS (50mM Tris HCl, 150mM KCl, pH 7.4). Elution of
FLAG-fusiontopoisomeraseIwasperformedbycompetition
withﬁvecolumnvolumesofasolutioncontaining100μg/mL
FLAG peptide in TBS. Fractions of 500μL were collected and
glycerol (ﬁnal concentration 40%) was added; all prepara-
tions were stored at –20◦C. The fractions were resolved by
SDS-polyacrylamide gel electrophoresis; protein concentra-
tionandintegrityweremeasuredthroughimmunoblotassay,
using the epitope-speciﬁc monoclonal antibody M2. After
normalization to protein content, the activity of the wild-
type and mutant DNA topoisomerase I, as assayed by relax-
ation of supercoiled DNA in 150mM KCl, was found to be
almostidentical.Inallthebiochemicalexperimentsthesame
amount of wild-type and mutated protein has been used.
2.3. Cleavage/Religation Equilibrium. The 25 mer oligonu-
cleotide, CL25 (5 -GAAAAAAGACTTAGAAAAATTTTTA-
3 ), was radiolabeled with [γ-32P]ATP at its 5  end. The
CP25 complementary strand (5 -TAAAAATTTTTCTAA-
GTCTTTTTTC-3 ) was phosphorylated at its 5  end with
unlabeled ATP. The two strands were annealed at a 2-fold
molar excess of CP25 over CL25. A ﬁnal concentration of
20nM duplex CL25/CP25 was incubated with an excess of
enzyme at 25◦Ci n2 0m MT r i sp H7 . 5 ,0 . 1m MN a 2EDTA,
10mM MgCl2,5 0μg/mL acetylated BSA, and 150mM KCl,
in the presence or absence of diﬀerent concentrations of
CPT. After 30 minutes, the reaction was stopped by adding
0.5% SDS and the sample was digested with trypsin after
precipitation with ethanol. Reaction products were resolved
in 16% acrylamide—7M urea gels, and the percentage of
cleavage (% Cl) was determined by PhosphorImager and
ImageQuant software.
2.4. Kinetics of Cleavage Using Oligonucleotide Substrate.
Oligonucleotide substrate CL14 (5 -GAAAAAAGACTTAG-
3 ) was radiolabeled with [γ-32P]ATP at its 5  end. The
CP25 complementary strand (5 -TAAAAATTTTTCTAA-
GTCTTTTTTC-3 ) was phosphorylated at its 5  end with
unlabeled ATP. The two strands were annealed at a 2-foldJournal of Amino Acids 3
molarexcessofCP25overCL14aspreviouslydescribed[18].
Thesuicidecleavagereactionswerecarriedoutbyincubating
20nM of the duplex with an excess of enzyme in 20mM
Tris pH 7.5, 0.1mM Na2EDTA, 10mM MgCl2,5 0 μg/mL
acetylated BSA, and 150mM KCl at 23◦Ci naﬁ n a lv o l u m e
of 50μL as described by Yang and Champoux [18]. A 5μL
sample of the reaction mixture was removed before addition
of the protein and used as the zero time point. At various
time points 5μL aliquots were removed and the reaction
stopped with 0.5% SDS. After precipitation with ethanol
samples were resuspended in 5μL of 1mg/mL trypsin
and incubated at 37◦C for 30min. Samples were analyzed
by denaturing urea/polyacrylamide gel electrophoresis. The
percentage bound cleavage product was determined by
PhosphorImager and ImageQuant software and normalized
on the total amount of radioactivity in each lane.
2.5. Kinetics of Religation Using Oligonucleotide Substrate.
20nM CL14/CP25, prepared as described above, was incu-
b a t e dw i t ha ne x c e s so fe n z y m ef o r6 0m i na t2 3 ◦C followed
by 30min at 37◦Ci n2 0m MT r i sp H7 . 5 ,0 . 1m MN a 2EDTA,
10mM MgCl2,5 0μg/mL acetylated BSA, and 150mM KCl.
Religation reactions were initiated by adding a 200-fold
molar excess of R11 oligonucleotide (5 -AGAAAAATTTT-
3 ) over the duplex CL14/CP25. At various time points 5μL
aliquots were removed and the reaction stopped with 0.5%
SDS. After ethanol precipitation samples were resuspended
in5μLof1mg/mLtrypsinandincubatedat37◦Cfor30min.
Samples were analyzed by denaturing urea/polyacrylamide
gelelectrophoresis.Thepercentageoftheremainingcovalent
complex was determined by PhosphorImager and Image-
Quant software and normalized on the total amount of
radioactivity in each lane.
2.6. MD Simulation. The DNA-Topo70 covalent complex,
without the N-terminal domain, has been modelled obtain-
ing the starting positions from the X-ray structure of 1a36
for residues 215–633 and 641–765 [6], and from the X-ray
structure 1ej9 for residues 203–214 [19]. The ﬁve residues
636–640 that form the loop connecting the linker domain
and the C-terminal domain, lacking in the 1a36 structure
in the Protein Data Bank (PDB http://www.rscb.org/pdb/),
and the covalent bond between the catalytic Tyr723 and
the −1 base, Thy10, have been added to the structure via
molecular modelling. The double mutant, obtained substi-
tuting Asp677 and Val703 with a glycine and an isoleucine,
respectively, has been minimized with the Powell method
implemented in the SYBYL program (Tripos, St. Louis,
MO), to establish the correct three-dimensional positioning
of the added residues and to normalize the stoichiometry
of the structures. The two systems were modelled with
the leaprc.ﬀ0 3f o r c eﬁ e l do fA M B E Rv e r s i o n8 . 0[ 20]a n d
solvated with TIP3P water molecules. Na+ counterions have
been added to neutralize the systems. The resulting systems
were composed of 9417 protein atoms, 1401 DNA atoms, 21
Na+ atoms,and35193watermoleculesforthenativeprotein,
for a total amount of 116418 atoms; 9415 protein atoms,
1401 DNA atoms, 20 Na+ atoms, and 39824 water molecules
for the mutant, for a total amount of 121056 atoms.
The two systems have been simulated for 10000 ps each,
using AMBER version 8.0 with periodic boundary condi-
tions, applying a cut-oﬀ of 9 ˚ A for nonbonding interactions
and updating neighbouring list every 10 steps. The electro-
static interactions were taken into account by means of the
particle mesh Ewald method [21, 22], and the SHAKE algo-
rithm [23] was used to restrict the length of hydrogen bonds.
Solventandionswereﬁrstoptimizedandrelaxedkeepingthe
solute atoms constrained to their starting positions, using a
decreasing force of 500, 25, 15, and 5kcal/(mol ˚ A). Systems
were simulated at a constant temperature of 300K using the
method of Ryckaert et al. [24] and at a constant pressure
of 1 bar with a 2.0 fs time step. Temperature and pressure
coupling constants were ﬁxed at 0.5 ps.
The analyses have been carried out on the last 10000 ps,
eliminating the equilibration step, which correspond to the
ﬁrst nanosecond. Hydrogen bonds, standard deviations
(RMSD),andﬂuctuations(RMSF)havebeencalculatedwith
the GROMACS MD package version 3.2.1 [25]( http://www
.gromacs.org/). The cut-oﬀ radius for direct hydrogen bond
distance was ﬁxed at 3.5 ˚ A, and the angle was ﬁxed at
120◦. The graphs were obtained with the Xmgrace program
(http://plasma-gate.weizmann.ac.il/Grace/) and the images
with VMD version 1.8.5 [26]( http://www.ks.uiuc.edu/Re-
search/vmd/).
3. Results
3.1. Eﬀect of CPT on the Cleavage-Religation Equilibrium.
To investigate the level of CPT hypersensitivity of the
Asp677Gly-Val703Ile mutant, the stability of the covalent
DNA-enzyme complex was studied using the 25mer full
duplex oligonucleotides substrate CL25 (5 -GAAAAAGAC-
TTAGAGAAAAATTTT-3 )/CP25 5 -TAAAAATTTTTC-
TAAGTCTTTTTTC-3 ). After 30 minutes of incubation
in the absence or presence of increasing concentrations of
CPT,thereactionproductswereanalyzedbypolyacrylamide-
urea gel electrophoresis (Figure 1). The results conﬁrm
that the double mutant is more sensitive to CPT since
the cleavage-religation equilibrium constant (Keq) is shifted
toward cleavage than the wild-type protein (cf. lanes 7–10
to 16–19). A slight shift toward cleavage can also be inferred
for the mutant in the absence of CPT, being the band due
to the cleavable complex slightly detectable (lane 11). Thus,
the DNA oligomer cleavage data support a change of the
enzyme sensitivity to CPT due to the two linker mutations,
in agreement with previous ﬁndings [11].
3.2. Cleavage and Religation Rate of Top1 and Top1 Dou-
ble Mutant. The DNA cleavage equilibrium constant Keq
is deﬁned by kcl/krl, that is, the ratio between cleavage
and religation rates. We have analyzed the single rates of
the enzyme catalytic cycle to shed light on the diﬀerent
behaviours of wild-type and mutant proteins. To inves-
tigate the eﬀect of the double mutation on the cleavage
reaction, a 5  end radiolabeled suicide substrate CL14 (5 -
GAAAAAGACTTAG-3 ) has been annealed to the CP25 (5 -
TAAAAATTTTTCTAAGTCTTTTTT-3 ) complementary4 Journal of Amino Acids
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Figure 1: Gel electrophoresis of the products coming from the
incubation of the wild-type topoisomerase I with the [γ-32P] end-
labelled duplex DNA, shown at the top of the ﬁgure in the absence
(lanes 2-3) or presence (lanes 4–10) of increasing amounts of CPT.
The arrow at the DNA sequence indicates the CL1 site preferred by
the wild-type protein. Lanes 11 and 12 and 13–19 show the same
experiment with the Asp677Gly-Val703Ile mutant.
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Figure 2: (a) Time course of the suicide cleavage reaction carried
out with the substrate described at the top of the ﬁgure. The arrow
indicates the preferential cleavage site for the wild-type protein. (b)
Percentage of the cleaved DNA substrate plotted as a function of
time for the wild-type (black line) and Asp677Gly-Val703Ile (red
line) mutant.
strand to produce a duplex with an 11-base 5  single-strand
extension (Figure 2(a)). With this substrate the religation
step is abolished because the short oligonucleotide generated
during cleavage cannot be religated, leaving the enzyme
covalently attached to the 3  end [18]. The suicide cleavage
substrate has been incubated with an excess of native and
mutated protein in a time course experiment. The amount
of cleaved fragment, normalized to the plateau value of the
topoisomerase,isplottedasafunctionoftimeinFigure 2(b).
The data show that both enzymes eﬃciently cleave the
suicide substrate at physiological ionic strength, reaching a
plateau level in approximately the same time.
The chemical step of DNA ligation was studied assaying
the ability of both enzymes to religate the oligonucleotide
R11 (5 -AGAAAAATTTT-3 ) once added to the precleaved
suicide substrate. The ﬁrst step of the reaction consists in
the incubation of an excess of native and mutated enzyme
with the suicide substrate for sixty minutes in order to
generate the cleaved complex having the enzyme covalently
attached to the 3  end. Once cleavage has occurred, the
R11 oligonucleotide is added to the mixture to initiate
the ligation process. Aliquots were removed at diﬀerent
times, the reaction stopped by addition of SDS, and the
products analyzed by polyacrylamide gel electrophoresis
(Figure 3(a)). The percentage of the remaining cleavable
complex, determined as described in Section 2,h a sb e e n
plotted as a function of time in Figure 3(b). The results show
thatthereligationrateismuchslowerforthemutantthanfor
the wild-type, indicating that mutation of the 677 and 703
residues of the linker domain decreases the religation process
likely whereas the cleavage process is practically unaﬀected.
3.3. Molecular Dynamics Simulation. The observation that
the main eﬀectof the double mutation is the reduction of the
religation rate suggests modiﬁed rearrangement of the active
site. In order to verify this hypothesis we have carried out a
10ns molecular dynamical simulation of the mutated system
and compared it with an identical simulation carried out for
the native enzyme.
The RMSD value for residues of the native and mutated
proteins as a function of time, calculated after a mass
weighted superposition on the starting structure, indicates
that for both systems the deviation from the starting
structure is mainly due to oscillation of the linker domain
since upon its elimination the RMSDs are stabilized (data
not shown). The deviation is smaller for the mutant (about
0.2nm)thanforthewild-type(about0.3nm)indicatingthat
the mutations reduce the conformational space sampled by
the protein (data not shown). Analysis of the per-residue
root mean square ﬂuctuation, RMSF, indicates a similar
behaviour,withthelinkerdomainbeingthemostﬂuctuating
region in both proteins (Figure 4). However, the double
mutant shows a lower degree of ﬂuctuation for each domain
when compared to the wild-type protein, and this is more
evident for the linker domain (residues 636–712) and for
the core domain, at the level of the “nose cone helices”
(residues 300–340). The diﬀerent degree of ﬂexibility can be
appreciated by overlapping the snapshots extracted from the
two dynamics taken every 200 ps as shown in Figure 5.T h eJournal of Amino Acids 5
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Figure 3: (a) Time course of the religation experiment between the R11 substrate and the covalent complex of the wild-type or Asp677Gly-
Val703Ile mutant. (b) Percentage of the remaining covalent complex, plotted at diﬀerent times for the wild-type enzyme (black line) and the
Asp677Gly-Val703Ile mutant (red line).
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Figure 4: Averaged per-residue RMSF represented as a function of
the hTop1 residue number for the native (black line) and mutated
(red line) enzyme.
wild-type protein (Figure 5(a)) samples a conformational
space larger than that observed for the double mutant
(Figure 5(b)). This is particularly evident for the linker
domain and the “nose cone helices,” where the diﬀerent
degrees of ﬂuctuation make the cavity that accommodates
the DNA larger in the mutant than that observed in the wild-
type.
The region around the active site has been analyzed in
detail to detect possible diﬀerences that might be correlated
with the experimentally observed reduction of the mutant
religation rate. Analysis of the time dependence of the
relative distances of the residues forming the catalytic pentad
indicates a structural-dynamical reorientation in the double
mutant, mainly at the level of Lys532. In the wild-type
protein the amino group of the lateral chain of Lys532
maintains a constant distance from the catalytic Tyr723 and
from the +1 adenine base (Ade11) of the scissile strand
over the entire simulation time, as shown in Figures 6(a)
and 6(b), black traces, in the latter case an almost constant
value of 0.3nm is found. For the mutant these distances are
longer and much more ﬂuctuating (Figures 6(a) and 6(b),
red traces). In detail a high degree of ﬂuctuation is observed
fortheLys532-Ade11distance,rangingfrom0.3to0.6nm.In
the case of the vaccinia topoisomerase it has been proposed
that the lateral chain of Lys167 (corresponding to human
Lys532) would accept a proton from the attacking 5 -OH
group of the +1 base in the religation step [27, 28]. A long
and ﬂuctuating 5 OH-NζLys532 distance, as that observed
in Figure 6(b), renders the donation of the proton more
diﬃcult, providing an explanation for the lower religation
rate of the mutant (Figure 3).
4. Discussion
The experimental cleavage-religation data reported in
Figure 1 conﬁrms that the Asp677Gly-Val703Ile double
mutant is more sensitive to CPT than the wild type. The
increase in CPT sensitivity is coupled to a reduction of the
religation rate as shown in Figure 3. This result emphasizes
the critical role of the linker domain and shows how muta-
tions in this domain can have an eﬀect on the catalytic site,
that is, in a region far from the mutations, demonstrating the
occurrence of communication between domains localized6 Journal of Amino Acids
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Figure 5:Overlapof50snapshotsextractedevery200psforthewild-type(a)andthedoublemutantenzyme (b)trajectories.Thestructures
have been superimposed on the Cα atoms of the active site residues Arg488, Arg590, and Tyr723. The “nose cone helices” are indicated by
an arrow. The sites of the two mutations on the linker domain are highlighted by a red sphere in the mutant structure.
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Figure 6: Atomic distance as a function of time between Lys532Nξ :Tyr723Oδ (a) and Lys532Nξ :Ade11O5  (b). Both distances have been
mediated every 50 frames. The black line and red traces represent the native protein and mutant protein data, respectively.
far away one from the other. The two mutations are in
fact widely separated from the drug binding site, the ﬁrst
one, Asp677Gly, being located in the loop connecting the
two linker α-helices, and the second one, Val703Ile, at the
bottom of the second linker helix (Figure 6(b)). Molecular
dynamics simulations provide some insight at the atomic
level of the camptothecin hypersensitivity and of the reduced
religation rate of the Asp677Gly-Val703Ile mutant. Analysis
of the trajectories evidences a lower ﬂexibility of the mutant
when compared to the wild-type, in particular for the linker
domain and the “nose cone helices” (Figures 4 and 5). In
a previous study, aimed at the characterization of the CPT
resistant single mutation Ala653Pro, the linker was found to
display a ﬂexibility larger than in the wild-type [9] whilst
a reduced religation rate coupled to an altered ﬂexibility
has been found in the Lys681Ala mutant [13]. The diﬀerent
ﬂexibility of the linker domain seems then to be directly
correlated to the enzyme sensitivity to camptothecin and to
the rate of the religation reaction. These ﬁndings are in line
with the fact that the linker domain is observed in the X-
ray diﬀraction of the crystal containing the ternary CPT-
DNA-topoisomerase complex, but not in the binary DNA-
topoisomerase complex [8], and a reduced linker mobility
has been shown by an MD study of the hTop1-DNA-
TPT ternary complex [10]. Likely, a high ﬂuctuating linker
domain induces a series of conformations that are less prone
to interact with the CPT molecule.
Another interesting result of the analysis of the tra-
jectories concerns the orientation and relative distance of
the residues belonging to the catalytic pentad. Four of theJournal of Amino Acids 7
ﬁve catalytic residues (Arg488, Arg590, His632, and Tyr723)
display an almost identical behaviour in both the native and
mutated enzyme. On the other hand, Lys532 in the mutant
is more ﬂuctuating and displays a large distance from both
the +1 adenine base 5  oxygen and the oxygen of Tyr723
(Figure 6). On the basis of studies carried out on the vaccinia
enzyme the lysine residue has been proposed to accept a
proton from the +1 base, downstream to the cleavage site
of the scissile strand, and to transfer it, directly or through
an arginine of the catalytic site, to the catalytic tyrosine, so
promoting the religation of the scissile strand [27, 28]. The
lengtheningofthisprotontransfer(Figure 6(b))ma ye xplain
at atomic level the lowered religation rate observed in the
mutant (Figure 3).
In conclusion, our study indicates that protein dynamics
plays an important role in the protein-DNA-drug com-
plex recognition. In detail the double Asp677Gly-Val703Ile
mutation makes the enzyme hypersensitive to camptothecin
inducing a reduction of the linker ﬂexibility coupled to a
slower religation rate, due to a partial destructuration of
the active site and in particular of the lengthening of the
distance between Lys532 and the +1 adenine base. Our study
conﬁrms the capability of the diﬀerent domains to interact
through long-range communication since mutations in the
linker domain can aﬀect regions of the protein far away, such
as the active site region. These ﬁndings support a model
where changes in linker ﬂexibility alter the geometry of the
active site with the consequent perturbation of the DNA
cleavage/religation reaction catalyzed by hTop1.
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